GSK buys 10% of CureVac in vaccine tech deal

GSK is to buy a 10% stake in German biotech company CureVac for 130 million pounds ($163.67 million), the two companies said on Monday, in a deal that bets on new technologies already being used in potential COVID-19 vaccines. GSK and CureVac, backed by Microsoft billionaire Bill Gates, will work on developing up to five so-called mRNA-based vaccines and...